<?xml version="1.0" encoding="UTF-8"?>
<p>This product contains dried flowers of female cannabis plants with 13% Δ9-THC and 1% CBD. It has similar effects as Bedrocan
 <sup>®</sup>, except that it has a lower THC content and acts poorly. Produced by the Office of Medicinal Cannabis (OMC) in the Netherlands, it is manufactured and marketed under the supervision of the Ministry of Health and used in smokery. Some of the therapeutic effects of Bedrobinol
 <sup>®</sup> include the treatment of spasticity associated pain in MS or spinal cord injury, the improvement of radiation-induced nausea and vomiting associated with cancers, radiation therapy and HIV therapy, all chronic pain conditions especially neuropathic pain, cachexia, anorexia in patients with cancer, AIDS, and anorexia nervosa [
 <xref rid="B167-molecules-25-04036" ref-type="bibr">167</xref>,
 <xref rid="B170-molecules-25-04036" ref-type="bibr">170</xref>]. Other products in this group have the same effects; however, each one contains a different composition of cannabinoids. Bediol
 <sup>®</sup>, Bedica
 <sup>®</sup>, and Bedrolite
 <sup>®</sup> are sold as finely-ground flower heads (granules), making them easier to use. The Bediol
 <sup>®</sup> granolate contains approximately 6.3% THC and 8% CBD. Bedica
 <sup>®</sup> contains approximately 14% THC and less than 1% CBD. Bedrolite
 <sup>®</sup> is composed of approximately 9% CBD and less than 1% THC.
</p>
